{"log_id": 2292864785689712373, "direction": 0, "words_result_num": 30, "words_result": [{"probability": {"variance": 1e-06, "average": 0.999282, "min": 0.994669}, "location": {"width": 923, "top": 149, "height": 56, "left": 138}, "words": "目前国内外儿童临床数据有限、需严密监测儿童患者的疗效和安全性,必要时及时调整"}, {"probability": {"variance": 0, "average": 0.999888, "min": 0.999787}, "location": {"width": 51, "top": 224, "height": 27, "left": 92}, "words": "剂量"}, {"probability": {"variance": 4e-06, "average": 0.999126, "min": 0.988263}, "location": {"width": 824, "top": 249, "height": 50, "left": 141}, "words": "本品用于3岁以上儿童及青少年的安全有效性信息主要来自国外临床研究数据"}, {"probability": {"variance": 0.000158, "average": 0.994658, "min": 0.936705}, "location": {"width": 920, "top": 297, "height": 51, "left": 141}, "words": "依据成人的剂量,推荐日剂量为:慢性期加速期和急变期340mg/m2(总剂量不超过600mg"}, {"probability": {"variance": 0.000193, "average": 0.996039, "min": 0.911179}, "location": {"width": 970, "top": 344, "height": 55, "left": 95}, "words": "日)制订儿童患者的每日推荐剂量,计算所得剂量一般应上下调整至整百毫克,12岁以下儿童"}, {"probability": {"variance": 7e-06, "average": 0.998381, "min": 0.99034}, "location": {"width": 393, "top": 405, "height": 40, "left": 96}, "words": "的剂量一般应上下调整至整五十毫克"}, {"probability": {"variance": 2.9e-05, "average": 0.997888, "min": 0.979521}, "location": {"width": 318, "top": 453, "height": 39, "left": 145}, "words": "尚无3岁以下儿童治疗的经验"}, {"probability": {"variance": 0.001166, "average": 0.984565, "min": 0.877393}, "location": {"width": 274, "top": 503, "height": 38, "left": 97}, "words": "Ph+ALL患者的治疗剂量"}, {"probability": {"variance": 0.002799, "average": 0.988409, "min": 0.681376}, "location": {"width": 759, "top": 538, "height": 49, "left": 147}, "words": "对难治复发成人Ph+ALL患者,甲磺酸伊马替尼的推荐剂量为600mg/日"}, {"probability": {"variance": 2.8e-05, "average": 0.997514, "min": 0.980155}, "location": {"width": 283, "top": 598, "height": 38, "left": 101}, "words": " HES/CEL患者的用药剂量"}, {"probability": {"variance": 0.003066, "average": 0.977925, "min": 0.822167}, "location": {"width": 637, "top": 635, "height": 48, "left": 148}, "words": "本品用于 HES/CEI治疗推荐剂量主要依据国外研究报道剂量"}, {"probability": {"variance": 0.006638, "average": 0.975409, "min": 0.525699}, "location": {"width": 920, "top": 679, "height": 51, "left": 149}, "words": "对于证明存在FIP1L1-PDGF-a融合激酶的HES/CEL,推荐起始剂量为100mg/日。如"}, {"probability": {"variance": 0.000152, "average": 0.997326, "min": 0.918149}, "location": {"width": 973, "top": 728, "height": 51, "left": 101}, "words": "果治疗后经适当检测证实未获得足够缓解,且无不良反应发生,可以考虑将100mg/日剂量增"}, {"probability": {"variance": 0.000666, "average": 0.986342, "min": 0.919371}, "location": {"width": 123, "top": 796, "height": 28, "left": 106}, "words": "至400mg/日"}, {"probability": {"variance": 0.000497, "average": 0.990895, "min": 0.924122}, "location": {"width": 231, "top": 837, "height": 39, "left": 107}, "words": "ASM患者的用药剂量"}, {"probability": {"variance": 1.2e-05, "average": 0.998011, "min": 0.988487}, "location": {"width": 599, "top": 875, "height": 48, "left": 153}, "words": "本品用于ASM治疗推荐剂量主要依据国外研究报道剂量"}, {"probability": {"variance": 0.000355, "average": 0.989908, "min": 0.919648}, "location": {"width": 924, "top": 918, "height": 53, "left": 153}, "words": "无D816Vc-Kit突变的ASM成人患者甲磺酸伊马替尼治疗推荐剂量是400mg/日。如果"}, {"probability": {"variance": 0.005384, "average": 0.985619, "min": 0.51605}, "location": {"width": 973, "top": 969, "height": 54, "left": 106}, "words": "ASM患者的c-Kit突变情况未知或无法测得,当使用其它疗法不能获得满意缓解时,应考虑"}, {"probability": {"variance": 0.001235, "average": 0.990832, "min": 0.837903}, "location": {"width": 422, "top": 1027, "height": 41, "left": 107}, "words": "给予甲磺酸伊马替尼400mg/日进行治疗"}, {"probability": {"variance": 0, "average": 0.747144, "min": 0.747144}, "location": {"width": 125, "top": 1027, "height": 37, "left": 840}, "words": " CEUTIC"}, {"probability": {"variance": 0.000732, "average": 0.987213, "min": 0.899392}, "location": {"width": 919, "top": 1064, "height": 51, "left": 155}, "words": "伴有嗜酸性粒细胞增多(一种与 FIPILI- PDGFR-α融合激酶有关的克隆性血液系统疾病"}, {"probability": {"variance": 0.000641, "average": 0.992841, "min": 0.837551}, "location": {"width": 969, "top": 1110, "height": 54, "left": 111}, "words": "的ASM患者,甲磺酸伊马替尼推荐起始剂量为100mg/日。如果治疗后经适当检测证实未获"}, {"probability": {"variance": 0.000428, "average": 0.992973, "min": 0.894764}, "location": {"width": 824, "top": 1162, "height": 53, "left": 111}, "words": "得足够缓解,且无不良反应发生,可以考虑将100mg剂量增至400mg"}, {"probability": {"variance": 2.1e-05, "average": 0.997328, "min": 0.983005}, "location": {"width": 293, "top": 1222, "height": 37, "left": 115}, "words": " MDS/MPD患者的用药剂量"}, {"probability": {"variance": 8e-06, "average": 0.998212, "min": 0.989144}, "location": {"width": 660, "top": 1258, "height": 49, "left": 161}, "words": "本品用于 MDS/MPD治疗推荐剂量主要依据国外研究报道剂量"}, {"probability": {"variance": 8.3e-05, "average": 0.995795, "min": 0.955079}, "location": {"width": 922, "top": 1302, "height": 53, "left": 164}, "words": "成人高嗜酸性粒细胞综合征和 PDGFR-α或-β基因重排的非典型 MDS/MPD患者推荐的"}, {"probability": {"variance": 0.000101, "average": 0.995471, "min": 0.95929}, "location": {"width": 394, "top": 1364, "height": 39, "left": 117}, "words": "甲磺酸伊马替尼用药剂量为400mg/日"}, {"probability": {"variance": 0.00053, "average": 0.989676, "min": 0.918776}, "location": {"width": 234, "top": 1416, "height": 32, "left": 123}, "words": "DFSP患者的治疗剂量"}, {"probability": {"variance": 1.4e-05, "average": 0.997884, "min": 0.984381}, "location": {"width": 602, "top": 1452, "height": 46, "left": 168}, "words": "本品用于DFSP治疗推荐剂量主要依据国外研究报道剂量"}, {"probability": {"variance": 0.001675, "average": 0.990707, "min": 0.737773}, "location": {"width": 919, "top": 1493, "height": 53, "left": 168}, "words": "成人DFSP患者甲磺酸伊马替尼治疗的推荐剂量是400mg/日。需要时剂量可升至每日"}], "language": 3}